Lymphotec Inc. has concluded a technology transfer agreement for the activated autologous lymphocyte therapy (Sekine method) with the Grand Zone Intl. Medical Group in Taiwan.
This is the second country for Lymphotec Inc. to have a technology transfer agreement after Korea. We aim to obtain the pharmaceutical approval from TFDA (the pharmaceutical agency in Taiwan) after clinical trials in Taiwan for the foreseeable future.
Lymphotec Inc. would like to widely contribute to the human health and medical treatment through overseas dissemination of the activated autologous lymphocyte therapy (Sekine method) continuously.